References
- Bogg A. Folliculitis decalvans. Acta Derm Venereol (Stockh) 1963; 43: 14–24
- Abeck D, Forting H C, Braun-Falco O. Folliculitis decalvans. Long-lasting response to combined therapy with fusidic acid and zinc. Acta Derm Venereol (Stockh) 1992; 72: 143–5
- Brozena S J, Cohen L E, Fenske NA. Folliculitis decalvans. Response to rifampin. Cutis 1988; 42: 512–15
- Rogolsky M. Nonenteric toxins of. Staphylococcus aureus. Microbiol Rev 1979; 43: 320–60
- Wehrli W. Rifampin: mechanism of action and resistance. Rev Infect Dis 1983; 5: S407–11, Suppl
- Dawber R PR, Ebling F JG, Wojnarowska FT. Disorders of hairs. Textbook of dermatology., RH Champion, JL Burton, FJG Ebling. Blackwell Scientific Publications, Oxford 1992; 2533–638
- Gupta S, Grieco M H, Siegel I. Suppression of T-lymphocyte rosettes by rifampin. Ann Intern Med 1975; 82: 484–8
- Mukerjee P, Schuldt S, Kasik JE. Effect of rifampin on cutaneous hypersensitivity to purified protein derivatives in humans. Antimicrob Agents Chemother 1973; 4: 607–11
- Bassi L, Di Berardino L, Arioli V, et al. Conditions for immunosuppression by rifampin. J Infect Dis 1973; 128: 736–44
- Buss W C, Morgan R, Guttman J, et al. Rifampicin inhibition of protein synthesis in mammalian cells. Science 1978; 200: 432–4
- Farr B, Mandell GL. Rifampin. Med Clin North Am 1982; 66: 157–68
- Marrack P, Kappler J. The staphylococcal enterotoxins and their relatives. Science 1990; 248: 705–11